About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Psoriasis Clinical Trials | 888 Studies Recruiting | Clareo Health

Clinical TrialsPsoriasis

Psoriasis Clinical Trials

Browse 888 clinical trials for psoriasis. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 501-520 of 888 trials

COMPLETEDPhase 2

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

NCT02407041

Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis

Galectin Therapeutics Inc.5 participantsStarted Sep 2015

San Antonio, Texas, United States

TERMINATEDPhase 2

AMG 827 in Subjects With Psoriatic Arthritis

NCT01516957

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Psoriatic Arthritis

Bausch Health Americas, Inc.168 participantsStarted Oct 2011

Peoria, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +28 more locations

Related Searches

psoriatictrials

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.

Bausch Health Americas, Inc.150 participantsStarted Jun 2016

Rogers, Arkansas, United States • Beverly Hills, California, United States • Carlsbad, California, United States +10 more locations

COMPLETEDPhase 4

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871

This study seeks to show whether there is a benefit of prescribing Enstilar in the treatment of patients with moderate plaque type psoriasis. Subjects will receive study treatment of Enstilar foam.

Plaque Psoriasis

Derm Research, PLLC20 participantsStarted Dec 2017

Louisville, Kentucky, United States

COMPLETEDPhase 3

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

NCT02899962

A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris. A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel group trial.

Psoriasis Vulgaris

LEO Pharma722 participantsStarted Feb 2017

Fremont, California, United States • Santa Monica, California, United States • Denver, Colorado, United States +55 more locations

COMPLETEDPhase 3

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

NCT02462122

Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis

Plaque Psoriasis

Bausch Health Americas, Inc.215 participantsStarted Aug 2015

Fremont, California, United States • Boynton Beach, Florida, United States • North Miami Beach, Florida, United States +13 more locations

COMPLETEDPhase 3

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Psoriatic Arthritis

Bausch Health Americas, Inc.484 participantsStarted Mar 2014

Peoria, Arizona, United States • Little Rock, Arkansas, United States • Cypress, California, United States +100 more locations

COMPLETEDPhase 3

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Enstilar® Foam (LEO Pharma Inc.) in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis)

Psoriasis Vulgaris

Glenmark Pharmaceuticals Ltd. India494 participantsStarted Oct 2018

Encinitas, California, United States • Fountain Valley, California, United States • San Diego, California, United States +27 more locations

Granulocytapheresis in Psoriasis

NCT00714272

In a prospective, randomized, controlled, double-blinded, multicenter study, granulocytapheresis using a novel cellulose-based adsorber will be compared to control sham treatment (placebo). The effects on clinical symptoms and on some inflammatory parameters of patients with moderate to severe plaque psoriasis will be evaluated over a 24-week period. The primary end-point is a ≥75 percent improvement in PASI (Psoriasis Area and Severity Index). The study purpose is to demonstrate a beneficial therapeutic effect of granulocytapheresis using the novel cellulose-based adsorber device in moderate to severe plaque psoriasis.

EXcorLab GmbH4 participantsStarted Feb 2008

Würzburg, Bavaria, Germany • Göttingen, Lower Saxony, Germany

COMPLETEDPhase 1/2

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

NCT03630939

This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114 following twice daily (BID) application for 42 days (6 weeks).

Psoriatic Plaque

Escalier Biosciences B.V.104 participantsStarted Aug 2018

Santa Monica, California, United States • Tampa, Florida, United States • Fridley, Minnesota, United States +7 more locations

Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study)

NCT03616561

Prospective open label non-randomized study, using Apremilast according to the manufacturer's Summary of Product Characteristics for 52 weeks, in patients with moderate to severe plaque psoriasis and nail psoriasis The study will be carried out in two hospital centers with experience in the management of patients with psoriasis and in the use of ultrasound of the nail apparatus. Visits and ultrasound would be performed by prescribing doctors themselves in their outpatient offices. Prior to the start of the study, the two doctors of each center will conduct a study to see the intraobserver and interobserver agreement on the ecographic parameters. The medication would be dispensed and controlled in the centers themselves and self-administered by patients at home. Each visit includes a ultrasound assessment of a target nail and measures of different scales: NAPSI, NAPPA.

Hospital de Granollers45 participantsStarted Feb 2018

Granollers, Barcelona, Spain

COMPLETEDPhase 4

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03573323

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

Plaque Psoriasis

Eli Lilly and Company1,027 participantsStarted Nov 2018

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +121 more locations

The Gut-Skin Axis Integrity in Psoriatic Patients

NCT04212507

Assess two non-invasive markers of intestinal barrier integrity {Claudin-3 and intestinal Fatty acid-binding protein (I-FABP)} in patients with psoriasis and to evaluate the possible relation of these markers with the demographic and clinical data.

Psoriatic Patients

Assiut University80 participantsStarted Oct 2020

Work Stress and Impact of Pruritus on Quality of Life

NCT04316533

Work stress and pruritus: imbalance of effort balance reward in patients with psoriasis.

University Hospital, Brest30 participantsStarted Mar 2020

Brest, Finistère, France

COMPLETEDPhase 3

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.

Psoriatic Arthritis

Amgen504 participantsStarted Jun 2010

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +89 more locations

COMPLETEDPhase 2

Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis

NCT00456092

This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.

Psoriatic Arthritis

Amgen204 participantsStarted Mar 2007

Brussels, Belgium • Diepenbeek, Belgium • Leuven, Belgium +35 more locations

COMPLETEDPhase 3

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

NCT02513550

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

Plaque Psoriasis

Eli Lilly and Company1,257 participantsStarted Aug 2015

Birmingham, Alabama, United States • Anaheim, California, United States • Beverly Hills, California, United States +122 more locations

The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis

NCT01818804

Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated atherosclerosis and increased cardiovascular risk. However, data regarding cardiovascular comorbidity and cardiovascular risk factors in patients with psoriatic arthritis are limited. Objective: The aim of this study is to investigate the effect of daily supplementation with 3 g n-3 polyunsaturated fatty acids on risk markers for cardiovascular disease and inflammation in patients with psoriatic arthritis. Design: Randomized double-blind, placebo-controlled, multicenter trial with n-3 polyunsaturated fatty acids in patient with psoriatic arthritis. Setting: Departments of Rheumatology, Nephrology and Cardiology at Aalborg University Hospital and Vendsyssel Hospital in Region Northern Denmark Participants: 156 men and women aged \> 18 years with psoriatic arthritis classified by the CASPAR criteria will be included. Exclusion criteria: cardiac arrhythmias, conduction disturbances, treatment with biological drugs or oral corticosteroids. Inclusion time: spring 2013 to spring 2015. Method: The following data will be collected for each participant: Interview including dietary records, assessment of tender and swollen joints, enthesitis, dactylitis, patient global assessment of disease activity (Visual Analogue Scale ), global assessment of pain (Visual Analogue Scale), psoriatic skin involvement by Psoriatic Area and Severity Index (PASI), laboratory parameters of disease activity and risk markers of cardiovascular disease. For detection of early cardiovascular risk markers Heart Rate Variability (HRV) and Pulse Wave Velocity (PWV) will be performed. Main outcome measures: The primary endpoint will be HRV and secondary endpoints will be PWV, inflammatory activity and use of analgesics. The trial is approved by The local Ethics Committee, registration number N20120076

Psoriatic Arthritis

Aalborg University Hospital145 participantsStarted Mar 2013

Aalborg, Denmark • Hjørring, Denmark

Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis

NCT02098694

The purpose of this study is to determine whether patients with spondyloarthritis are more satisfied with a physiotherapy-led outpatient clinic than usual care and whether there is a difference between patients in a physiotherapy-led outpatient clinic and those in usual care regarding disease activity, function and mobility.

SpondylarthritisSpondylitis, AnkylosingSpondylarthropathies+2 more

Norwegian University of Science and Technology62 participantsStarted Jun 2014

Ålesund, Norway

COMPLETEDEARLY Phase 1

Using an Internet Study to Improve Adherence for Psoriasis Patients

NCT01802580

To evaluate whether participation in an Internet-based intervention helps improve short-term and long-term psoriasis treatment outcomes, in particular, adherence.

Wake Forest University40 participantsStarted Oct 2012

Winston-Salem, North Carolina, United States

PreviousPage 26 of 45Next